Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL

CompletedOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions
Myelodysplastic Syndromes
Trial Locations (21)

1000

Institute Jules Bordet, Brussels

1090

UZ Brussel, Jette

1200

Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert

2020

Ziekenhuis Netwerk Antwerpen, Antwerp

2240

Sint-Dimpna Ziekenhuis Geel, Geel

2500

Heilig Hart Ziekenhuis, Lier

2610

GasthuisZusters Antwerpen, Antwerp

2650

UZA, Edegem

2820

Imelda, Bonheiden

2930

AZ KLINA, Brasschaat

3000

UZ Leuven Gasthuisberg, Leuven

5000

CHR Namur, Namur

5530

CHU - UCL Namur site Godinne, Yvoir

7000

CHR Mons Hainaut, Mons

CHU Ambroise Paré, Mons

7100

CH Jolimont, La Louvière

8000

AZ Sint Jan Brugge, Bruges

8400

AZ Damiaan Oostende, Ostend

9000

UZ Gent, Ghent

9100

AZ Nikolaas, Sint-Niklaas

Unknown

BR Clinic Saint Pierre Ottignies, Ottignies-Louvain-la-Neuve

All Listed Sponsors
lead

University Hospital, Antwerp

OTHER

NCT04053933 - Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL | Biotech Hunter | Biotech Hunter